<?xml version="1.0" encoding="UTF-8"?>
<p id="p0060">Several convalescent blood products such as intravenous immunoglobulins (IVIg) and polyclonal or monoclonal antibodies have been developed to treat infectious conditions [
 <xref rid="bb0090" ref-type="bibr">18</xref>]. However, in situations of emergency, they are difficult and expensive to produce, and may not yield an appropriate infectious control. Thus, the use of CP has been widely used in different outbreaks as the first therapeutic option given the lack of effective medications or vaccines, and often as last chance or experimental treatment [
 <xref rid="bb0130" ref-type="bibr">26</xref>].
</p>
